北京若生智能科技有限公司
Drug Database
TE

tetracaine + lidocaine (Pliaglis / TetraPeel / Pliaglis)

✓ Approved

Sun Pharmaceutical Industries Ltd. · SCN9A · 小分子

什么是 tetracaine + lidocaine？

tetracaine + lidocaine 是一种小分子，由Sun Pharmaceutical Industries Ltd.研发。该药已获批，用于治疗相关适应症，给药途径：Topical。

药物档案

商品名Pliaglis, TetraPeel, Pliaglis
公司Sun Pharmaceutical Industries Ltd.
药物类别小分子
分子靶点SCN9A
给药途径Topical
状态Approved
来源： ClinicalTrials.gov, Sun Pharmaceutical Industries Ltd.

作用机制

分子靶点

tetracaine + lidocaine 作用于 1 个分子靶点：

SCN9Asodium voltage-gated channel alpha subunit 9 (SFNP, GEFSP7)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

tetracaine + lidocaine 针对 2 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Nervous system disordersAnaesthesia✓ Approved
Nervous system disordersSensory loss✓ Approved

相关研究文献

PubMedJournal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia2026-09-09

Middle meningeal artery lidocaine infusion reduces headache after venous sinus stenting for idiopathic intracranial hypertension.

Sequeiros Joel J, Abo Kasem Rahim R, Becerril-Gaitan Andrea A, Terry Fernando F et al.

Headaches after venous sinus stenting (VSS) for idiopathic intracranial hypertension (IIH) are very common and challenging to manage. We evaluated the safety and efficacy of middle meningeal artery (MMA) lidocaine infusion to mitigate post-VSS cephalalgia. We retrospectively reviewed 50 consecutive patients with medically refractory IIH who underwent VSS at a single institution (February 2024-January 2026). Seven patients received bilateral MMA infusion of 50 mg of 1% lidocaine immediately following stent deployment; 43 patients served as controls. The primary outcome was first-day headache burden (normalized sum of VAS scores). Secondary outcomes included total in-hospital opioid consumption (oral morphine equivalents, OME) and procedural complications. Baseline characteristics and procedural metrics were comparable between groups. The MMA lidocaine infusion group demonstrated a 52% reduction in median first-day headache burden compared to controls (15.1 vs. 31.0; P = 0.012). Opioid consumption was reduced by 83.2% in the treatment arm (median 2.8 mg vs. 16.7 mg; P = 0.008). No complications related to MMA infusion occurred, and all infused MMAs remained patent. No seizures or other neurological or cardiovascular complications were observed. MMA lidocaine infusion may significantly reduce acute pain burden and opioid requirements following VSS in IIH patients. Prospective trials are warranted to confirm the safety and efficacy of this intervention.

PMID 42715927
阅读全文 →
PubMedJournal of lower genital tract disease2026-09-09

Intralesional Corticosteroid Therapy for Refractory Hyperkeratotic Vulvar Lichen Sclerosus: A Case Series.

Murciano-López José Martín JM, Lorente-Lavirgen Ana Isabel AI, Coronel Pérez Isabel María IM, Castilla-de Dios Alejandro A et al.

To describe clinical response and safety of intralesional corticosteroid therapy for adult patients with persistent or refractory hyperkeratotic vulvar lichen sclerosus after histologic exclusion of neoplasia. This was a descriptive case series of 3 adult women with vulvar lichen sclerosus and persistent hyperkeratotic plaques despite topical corticosteroid therapy. All patients underwent vulvar biopsy before intervention to exclude human papillomavirus-associated vulvar intraepithelial neoplasia, human papillomavirus-independent vulvar intraepithelial neoplasia, or squamous cell carcinoma. A single session used 0.25 mL triamcinolone acetonide 40 mg/mL diluted 1:1 with 0.25 mL 2% lidocaine (final concentration, 20 mg/mL; total dose, 10 mg) delivered through 4 to 6 points with a 0.5-mL insulin syringe and 0.30×8-mm needle. There was no comparator. Outcomes were clinical resolution, symptoms, Vulvar Quality of Life Index (VQLI) score, photographs, and adverse events. No statistical analysis was performed because of the descriptive design and small sample size. All patients showed complete clinical resolution at 4 months and no repeat infiltration. VQLI scores decreased from 35 to 12, 31 to 8, and 22 to 10, respectively. At March 2026 follow-up (median: 11 mo; range: 10 to 12), no clinical recurrence or local/systemic adverse events were observed or reported. The main limitations were the small number of cases, lack of a control group, descriptive design, and short follow-up. Intralesional triamcinolone may be a useful rescue therapy for selected patients with persistent or refractory hyperkeratotic vulvar lichen sclerosus, provided that neoplasia is excluded and long-term surveillance is maintained.

PMID 42715226
阅读全文 →
PubMedJournal of dairy science2026-09-09

A randomized field study comparing 2 cautery disbudding techniques on wound healing in dairy calves.

Singh A A, Mann S S, Grosul A A, Wieland M M

Disbudding is a routine management practice on dairy farms, and cautery disbudding remains the most popular method in North America. Practitioners commonly employ 2 methods of cautery disbudding: retaining (BUD-IN) or removing (BUD-OUT) the cauterized horn bud. However, comparative evidence regarding healing and pain outcomes between these techniques is limited. The objective of this study was to compare pain sensitivity, wound characteristics, healing outcomes, and growth performance following cautery disbudding with BUD-IN or BUD-OUT in heifer dairy calves. We hypothesized that pain sensitivity and wound healing characteristics would differ between these 2 cautery disbudding methods. A total of 222 healthy female Holstein calves were enrolled at 16 d of age on a commercial dairy farm in New York and randomly assigned to BUD-IN (n = 111) or BUD-OUT (n = 111) treatment groups. All calves received meloxicam (1 mg/kg BW, orally) and a cornual nerve block with 5 mL of 2% lidocaine before disbudding. Wound diameter was the primary outcome variable. Other secondary outcome variables were mechanical nociceptive threshold (MNT), wound discharge, wound healing score, and calf health. All outcome variables were assessed weekly for 8 wk. Body weight was measured at disbudding (wk 0) and 8 wk after disbudding. The continuous outcomes MNT, wound diameter, and ADG were analyzed using generalized linear mixed models; the binary outcome (presence or absence of wound discharge) was analyzed using logistic regression; and time to complete healing was analyzed using Cox proportional hazards regression. Mechanical nociceptive threshold and wound diameter did not differ between groups. Wound discharge was observed during the initial 4 wk post-disbudding. Purulent wound discharge was more common in BUD-IN than BUD-OUT, with an odds ratio (95% CI) of purulent wound discharge in BUD-IN. Time to complete wound healing did not differ between treatments. Average daily gain was not different among groups. Under the conditions of this study, removal of the horn bud during cautery disbudding did not affect pain sensitivity, growth performance, or time to wound healing but was associated with reduced odds of early wound discharge. These findings suggest that both techniques produce comparable long-term outcomes when appropriate analgesia is provided, and the selection of technique may be guided by early wound management considerations.

PMID 42716290
阅读全文 →
PubMedPakistan journal of pharmaceutical sciences2026-09-08

Intravenous lidocaine reduces the propofol EC50 for loss of consciousness and intraoperative anesthetic consumption in gynecological laparoscopy: A randomized controlled trial.

Jin Lin L, Pan Panpan P, Wang Jialin J, Chen Xiaoping X et al.

Intravenous lidocaine reduces propofol requirements and procedure-related adverse events. The study aimed to test whether intravenous lidocaine would reduce the effect-site concentration of propofol required to achieve loss of consciousness and decrease propofol consumption during total intravenous anesthesia in gynecological laparoscopy. This was a prospective, randomized, double-blind, placebo-controlled trial. Sixty patients were randomly allocated to receive either intravenous lidocaine (1.5 mg·kg-¹ bolus) followed by continuous infusion or an equal volume of saline. Propofol was administered via target-controlled infusion starting at an effect-site concentration of 3.5 μg/mL. The concentration was then adjusted in steps of 0.5 μg/mLaccording to Dixon's up-and-down sequential method: decreased if loss of consciousness was achieved, or increased if not. Loss of consciousness was defined as loss of response to verbal commands. The median effective concentration (EC50) of propofol for inducing loss of consciousness was calculated using the Dixon's up-and-down method. General anesthesia was maintained with propofol and remifentanil, guided by state entropy (target 40-60) and surgical pleth index (target 20-50). Drug consumption was normalized to anesthesia duration and body weight. The estimated EC50 of propofol for inducing loss of consciousness was significantly lower in the lidocaine group than in the saline group (3.32 μg/mL, 95% Confidence Interval (CI): 3.04-3.59 vs. 3.89 μg/mL, 95% CI: 3.50-4.28). Under the study protocol, the lidocaine group also required less propofol (8.62 mg·kg-1·h-1, 95% CI: 8.10-9.15 vs. 9.89 mg·kg-1·h-1, 95% CI: 9.05-10.73) and less remifentanil (0.23 μg·kg-1·min-1, 95% CI: 0.21-0.24 vs. 0.27 μg·kg-1·min-1, 95% CI: 0.24-0.30) compared with the saline group. Intravenous lidocaine reduced the propofol EC50 for Loss of Consciousness (LOC) and decreased intraoperative propofol and remifentanil consumptions in patients undergoing gynecological laparoscopy. These findings suggest a propofol- and opioid-sparing effect of intravenous lidocaine in this setting, although confirmation in larger multicenter trials is needed.

PMID 42708800
阅读全文 →
PubMedBMJ open2026-09-08

Impact of PerioperAtive LidocAine Infusions on Enhanced Recovery After Noncardiac Surgery (IMPALA-ERAS) in an inpatient setting: rationale, design and protocol for a sequential, repeated crossover trial.

Rouleau Gerald W GW, Smith Aden W AW, Parrish Crystal G CG, Allen Leslie J LJ et al.

Multimodal analgesic strategies designed to minimise perioperative opioid exposure are fundamental components of enhanced recovery after surgery (ERAS) pathways. Despite widespread implementation of ERAS protocols, the optimal analgesic regimen remains undefined, as the individual contributions of specific agents to overall analgesic efficacy and opioid-sparing effects are not fully elucidated. Intravenous lidocaine, a widely utilised local anaesthetic, possesses both analgesic and anti-inflammatory properties and has been associated with improved gastrointestinal recovery. This study seeks to pragmatically evaluate the impact of incorporating perioperative intravenous lidocaine infusion into established ERAS pathways on postoperative functional recovery. The Impact of PerioperAtive LidocAine Infusions (IMPALA) on ERAS trial is a single-centre, pragmatic, cluster-randomised, double-blinded, placebo-controlled study. A total of 2290 patients undergoing elective colorectal surgery, emergency general surgery, urology, ventral hernia repair, surgical oncology or spine surgery will be randomly assigned to receive either intraoperative and postoperative intravenous lidocaine infusions (administered for up to 48 hours) or placebo as part of a standardised multimodal analgesic regimen integrated into established ERAS pathways. The primary outcome is case mix index-adjusted resource length of stay, defined as the time interval from surgical initiation to hospital discharge adjusted for case mix index. The primary outcome is total inpatient opioid consumption within the first 72 hours, reported in oral morphine milligram equivalents. Secondary outcomes include various in-hospital clinical endpoints derived from the electronic health record. This protocol and accompanying statistical analysis plan outline the study design, primary and secondary endpoints and analytic methodology. The IMPALA-ERAS trial has received ethical approval from the Vanderbilt University Institutional Review Board (IRB: 250617). The findings will be disseminated via peer-reviewed publications and presentations at national conferences. Results from this trial are expected to inform evidence-based practices regarding perioperative lidocaine infusion and its potential contributions to enhanced postoperative recovery in surgical patients. NCT07224711.

PMID 42711072
阅读全文 →
PubMedJournal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia2026-09-08

Comparison of subanaesthetic ketamine and lidocaine as adjuvants to propofol-based total intravenous anesthesia on propofol requirement during emergency decompressive craniectomy for traumatic brain injury: a prospective, double-blind, three-arm randomized controlled trial.

Ramadurai Rajasekar R, Swaminathan Srinivasan S, Bidkar Prasanna Udupi PU, Seshan Jayanth R JR et al.

Prevention of secondary brain injury remains a key objective during emergency decompressive craniectomy for traumatic brain injury (TBI). Propofol-based total intravenous anesthesia (TIVA) is widely used in TBI because of its favorable cerebral physiological effects but may cause dose-dependent hypotension and compromise cerebral perfusion. Ketamine and lidocaine have been proposed as adjuncts that may reduce anesthetic requirements while preserving intracranial homeostasis. This study compared the effects of ketamine and lidocaine versus placebo on propofol consumption and perioperative intracranial pressure (ICP), cerebral perfusion pressure (CPP), and brain relaxation during TIVA in patients undergoing emergency decompressive craniectomy for TBI. In this prospective, double-blind, three-arm randomized controlled trial, 150 adults undergoing emergency decompressive craniectomy for traumatic acute subdural hematoma were randomized to receive adjunctive ketamine (0.5 mg/kg/h), lidocaine (2 mg/kg/h), or placebo during propofol-based TIVA. Propofol was administered using target-controlled infusion (TCI) to maintain mean arterial pressure within 20% of baseline. The primary outcome was mean propofol consumption (µg/kg/min). Secondary outcomes included intraoperative opioid consumption, vasopressor requirement, ICP, CPP, brain relaxation, and neurological outcomes. Mean propofol consumption differed significantly among groups and was lowest with ketamine (100.73 ± 31.72 vs. 115.86 ± 38.11 vs. 131.53 ± 44.54 µg/kg/min for ketamine, lidocaine, and placebo, respectively; p < 0.001). Ketamine was also associated with lower intraoperative fentanyl requirements (63.85 ± 36.23 vs. 83.64 ± 32.27 vs. 153.55 ± 57.28 µg; p < 0.001) and fewer vasopressor boluses (2 [2-3] vs. 3 [2-4] vs. 3 [2-4]; p = 0.031). Intracranial pressure, cerebral perfusion pressure, brain relaxation scores, and Glasgow Outcome Scale-Extended scores were comparable among the groups. Ketamine as an adjunct to propofol-based TIVA reduced propofol, opioid, and vasopressor requirements. As TIVA was titrated to haemodynamic responses rather than processed EEG, the relative contributions of direct propofol-sparing and ketamine's sympathomimetic effects cannot be determined. No detrimental effects on intracranial pressure, cerebral perfusion pressure, or brain relaxation were detected at the measured intraoperative time points, and no between-group differences in neurological outcomes were detected. Lidocaine demonstrated modest propofol-sparing effects without adverse effects on measured intracranial dynamics.

PMID 42710328
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多tetracaine + lidocaine